🚀 VC round data is live in beta, check it out!
Ono Pharmaceutical Valuation Multiples
Discover revenue and EBITDA valuation multiples for Ono Pharmaceutical and similar public comparables like Grifols, Kymera Therapeutics, Alkem Laboratories, Apogee Therapeutics and more.
Ono Pharmaceutical Overview
About Ono Pharmaceutical
Ono Pharmaceutical Co Ltd is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. The vast majority of the company's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of the company's sales is generated in Japan, followed by the rest of Asia and Europe.
Founded
1947
HQ
Employees
4.3K
Website
Sectors
Financials (LTM)
EV
$7B
Ono Pharmaceutical Financials
Ono Pharmaceutical reported last 12-month revenue of $3B and EBITDA of $844M.
In the same LTM period, Ono Pharmaceutical generated $2B in gross profit, $844M in EBITDA, and $453M in net income.
Revenue (LTM)
Ono Pharmaceutical P&L
In the most recent fiscal year, Ono Pharmaceutical reported revenue of $3B and EBITDA of $726M.
Ono Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3B | XXX | $3B | XXX | XXX | XXX |
| Gross Profit | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Margin | 75% | XXX | 63% | XXX | XXX | XXX |
| EBITDA | $844M | XXX | $726M | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 22% | XXX | XXX | XXX |
| EBIT Margin | 20% | XXX | 12% | XXX | XXX | XXX |
| Net Profit | $453M | XXX | $623M | XXX | XXX | XXX |
| Net Margin | 14% | XXX | 19% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Ono Pharmaceutical Stock Performance
Ono Pharmaceutical has current market cap of $7B, and enterprise value of $7B.
Market Cap Evolution
Ono Pharmaceutical's stock price is $15.12.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7B | $7B | -3.7% | XXX | XXX | XXX | $1.33 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOno Pharmaceutical Valuation Multiples
Ono Pharmaceutical trades at 2.1x EV/Revenue multiple, and 7.9x EV/EBITDA.
EV / Revenue (LTM)
Ono Pharmaceutical Financial Valuation Multiples
As of April 18, 2026, Ono Pharmaceutical has market cap of $7B and EV of $7B.
Equity research analysts estimate Ono Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ono Pharmaceutical has a P/E ratio of 15.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7B | XXX | $7B | XXX | XXX | XXX |
| EV (current) | $7B | XXX | $7B | XXX | XXX | XXX |
| EV/Revenue | 2.1x | XXX | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | 7.9x | XXX | 9.2x | XXX | XXX | XXX |
| EV/EBIT | 10.2x | XXX | 16.3x | XXX | XXX | XXX |
| EV/Gross Profit | 2.8x | XXX | 3.1x | XXX | XXX | XXX |
| P/E | 15.7x | XXX | 11.4x | XXX | XXX | XXX |
| EV/FCF | 17.4x | XXX | 14.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Ono Pharmaceutical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Ono Pharmaceutical Margins & Growth Rates
Ono Pharmaceutical's revenue in the last 12 month declined by (9%).
Ono Pharmaceutical's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $0.4M for the same period.
Ono Pharmaceutical's rule of 40 is 22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ono Pharmaceutical's rule of X is 14% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Ono Pharmaceutical Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (9%) | XXX | (4%) | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Growth | (3%) | XXX | 16% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 22% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 14% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 26% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 24% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 29% | XXX | 31% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 52% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Ono Pharmaceutical Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Ono Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Grifols | XXX | XXX | XXX | XXX | XXX | XXX |
| Kymera Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Alkem Laboratories | XXX | XXX | XXX | XXX | XXX | XXX |
| Apogee Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Merus | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ono Pharmaceutical M&A Activity
Ono Pharmaceutical acquired XXX companies to date.
Last acquisition by Ono Pharmaceutical was on XXXXXXXX, XXXXX. Ono Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Ono Pharmaceutical
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOno Pharmaceutical Investment Activity
Ono Pharmaceutical invested in XXX companies to date.
Ono Pharmaceutical made its latest investment on XXXXXXXX, XXXXX. Ono Pharmaceutical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Ono Pharmaceutical
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Ono Pharmaceutical
| When was Ono Pharmaceutical founded? | Ono Pharmaceutical was founded in 1947. |
| Where is Ono Pharmaceutical headquartered? | Ono Pharmaceutical is headquartered in Japan. |
| How many employees does Ono Pharmaceutical have? | As of today, Ono Pharmaceutical has over 4K employees. |
| Who is the CEO of Ono Pharmaceutical? | Ono Pharmaceutical's CEO is Gyo Sagara. |
| Is Ono Pharmaceutical publicly listed? | Yes, Ono Pharmaceutical is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of Ono Pharmaceutical? | Ono Pharmaceutical trades under 4528 ticker. |
| When did Ono Pharmaceutical go public? | Ono Pharmaceutical went public in 1963. |
| Who are competitors of Ono Pharmaceutical? | Ono Pharmaceutical main competitors are Grifols, Kymera Therapeutics, Alkem Laboratories, Apogee Therapeutics. |
| What is the current market cap of Ono Pharmaceutical? | Ono Pharmaceutical's current market cap is $7B. |
| What is the current revenue of Ono Pharmaceutical? | Ono Pharmaceutical's last 12 months revenue is $3B. |
| What is the current revenue growth of Ono Pharmaceutical? | Ono Pharmaceutical revenue growth (NTM/LTM) is (9%). |
| What is the current EV/Revenue multiple of Ono Pharmaceutical? | Current revenue multiple of Ono Pharmaceutical is 2.1x. |
| Is Ono Pharmaceutical profitable? | Yes, Ono Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Ono Pharmaceutical? | Ono Pharmaceutical's last 12 months EBITDA is $844M. |
| What is Ono Pharmaceutical's EBITDA margin? | Ono Pharmaceutical's last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Ono Pharmaceutical? | Current EBITDA multiple of Ono Pharmaceutical is 7.9x. |
| What is the current FCF of Ono Pharmaceutical? | Ono Pharmaceutical's last 12 months FCF is $384M. |
| What is Ono Pharmaceutical's FCF margin? | Ono Pharmaceutical's last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of Ono Pharmaceutical? | Current FCF multiple of Ono Pharmaceutical is 17.4x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.